EyePoint plummets on pivotal data for main drug

EyePoint drug fails pivotal trial, company loses nearly $1 billion in market value

Boston-area biotechnology company EyePoint's main drug candidate failed to hit the central goal of its pivotal LUGANO trial for vision treatment, causing shares to plummet and wiping out nearly a billion dollars in market value.